Health Care Distributors

HUADONG MEDICINE

HUADONG MEDICINE released FY2025 earnings on April 23 After-Market (BJT), actual revenue CNY 43.61 B (forecast CNY 44.29 B), actual EPS CNY 1.9465 (forecast CNY 2.1991)

HUADONG MEDICINE released FY2026 Q1 earnings on April 23 After-Market (BJT), actual revenue CNY 11.18 B (forecast CNY 12.19 B), actual EPS CNY 0.5715 (forecast CNY 0.59)

HUADONG MEDICINE released FY2025 Q4 earnings on April 23 After-Market BJT, actual revenue CNY 10.95 B (forecast CNY 11.35 B), actual EPS CNY 0.3799 (forecast CNY 0.5347)

HUADONG MEDICINE to Release FY2026 Q1 Earnings on April 24 After-Market BJT, Forecast Revenue CNY 12.19 B, EPS CNY 0.59

HUADONG MEDICINE to Release FY2025 Earnings on April 24 After-Market (BJT), Forecast Revenue CNY 44.29 B, EPS CNY 2.1991

HUADONG MEDICINE released FY2025 9 Months earnings on October 27 After-Market (BJT), actual revenue CNY 32.66 B, actual EPS CNY 1.5658

HUADONG MEDICINE released FY2025 Q3 earnings on October 27 After-Market (BJT), actual revenue CNY 10.99 B (forecast CNY 11.25 B), actual EPS CNY 0.5375 (forecast CNY 0.5323)

HUADONG MEDICINE to Release FY2025 Q3 Earnings on October 28 After-Market (BJT), Forecast Revenue CNY 11.25 B, EPS CNY 0.5323

HUADONG MEDICINE released FY2025 Semi-Annual Earnings on August 19 After-Market (BJT), actual revenue CNY 21.67 B, actual EPS CNY 1.0293

HUADONG MEDICINE released FY2025 Q2 earnings on August 19 After-Market (BJT), actual revenue CNY 10.94 B (forecast CNY 11.74 B), actual EPS CNY 0.507 (forecast CNY 0.5)

Huadong Medicine Introduces Its Product Pipeline in Weight Loss and Diabetes Management

HUADONG MEDICINE to Release FY2025 Semi-Annual Earnings on August 20, 2025 (BJT)

Huadong Medicine Releases HDM1002 Weight Loss Phase II Clinical Data

Huadong Medicine's HDM1002 Weight Loss Phase II Clinical Trial Results Excellent

China-Me East and West Applying for Marketing Authorization for Edaravone Tablets for Acute Ischemic Stroke

Huadong Medicine Secretary Responds to Impact of Long-acting Insulin Launch

Hangzhou China-US Huadong Pharmaceutical Obtains Approval for Psoriasis Cream Clinical Trials

Hangzhou China-US Huadong Pharmaceutical's Injection Acarbose Approved by US FDA

Sinclair and Huaheng Pharmaceutical's HDM1002 Clinical Trial Approved by FDA

Huadong Medicine Receives Approval for Late-Stage Solid Tumor Drug Clinical Trial

00512

513700

159992

520690

000963

588130

159316

562050

516930

512290

Grand Pharmaceutical Group (SEHK:512) has received China approval for eye treatment GPN01768 and advanced migraine drug GPN01020 to Phase II trials. The stock trades at HK$7.22, with a 6.49% return over the past week but a 7.44% decline over 90 days. The P/E ratio of 20.4x suggests good value compared to its fair P/E of 25.1x and peer average of 21.6x, despite risks from clinical trials and revenue concentration. A DCF model estimates a future cash flow value of HK$22.44 per share, indicating a significant valuation gap.

Simplywall

GRANDPHARMA

Penghua CSI HK Connect Health Care Composite ETF

Yinhua CSI Innovative Drugs Industry ETF

Bosera Hang Seng Health Care ETF(QDII)

China Merchants CSI All Share Medical Apparatus and Instruments ETF

ChinaAMC SSE Health Care ETF Initiating Fund

ChinaAMC CSI Biotechnology Theme ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

ChinaAMC SSE STAR Biology and Medicine ETF

E Fund Hang Seng SCHK Innovative Drug ETF

GRAND HOLDING

China Universal CNI HK Connect Innovative Drugs Industry ETF

E Fund CSI 300 Health Care ETF

E Fund CSI Biotechnology Theme ETF

Hwabao WP CSI Pharmaceuticals ETF

Minsheng Royal CSI Biotechnology Theme ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Guotai CSI Bio-medicine ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

ChinaAMC CSI All Share Health Care Devices ETF

Assessing Grand Pharmaceutical Group (SEHK:512) Valuation After China Drug Approvals And Earnings Update

CS精准医

159849

159929

Belief BioMed and Grand Life Sciences have announced an exclusive partnership to commercialize BBM-H803, a gene therapy for hemophilia A, in China, Hong Kong, Macau, and Taiwan. This collaboration aims to leverage both companies' strengths to accelerate the commercialization process and improve patient access to innovative treatments. The agreement was signed by key executives from both companies, highlighting their commitment to addressing the unmet clinical needs of hemophilia A patients. BBM-H803 is an AAV-based gene therapy designed to enhance coagulation factor levels in patients, with ongoing trials and regulatory approvals in place.

prnewswire

China Merchants CSI Biotechnology Theme ETF

Guotai SSE STAR Brand Name Drug ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

China Universal 800 Health Care ETF

01:48 ETBelief BioMed and Grand Life Sciences Announced Exclusive Commercial Partnership in the Field of Hemophilia A, Bringing Innovative Gene Therapy to Chinese Patients

SXTC

Grand Pharmaceutical Wins China’s First Approval for Demodex Blepharitis Drug, Bolstering Ophthalmic Push

Tip Ranks

China SXT Pharmaceuticals

Grand Pharmaceutical Wins China’s First Approval for Demodex Blepharitis Drug, Bolstering Ophthalmic Push

East China Pharmaceutical's subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., has received FDA approval for a Phase I clinical trial in the U.S. The trial will focus on the injectable drug HDM2024, aimed at treating advanced solid tumors. This approval is a significant milestone for the company's international research and development efforts.

CoinLive

East China Pharmaceutical Subsidiary Receives FDA Approval for Clinical Trial

002038

On January 31, according to the National Healthcare Security Administration, the new national medical insurance drug list will be fully implemented in Guangxi starting from January 1, 2026. In this adjustment of the list, the National Healthcare Security Administration has included "Deferasirox Tablets" in the national medical insurance drug list through negotiations, effectively addressing the medical needs of patients with thalassemia and reducing the medication burden on insured patients' families. Before being included in medical insurance, urban and rural residents' patients incurred nearly 3,000 yuan in out-of-pocket expenses per month for treatment at designated institutions in cities and counties. After being included in medical insurance, the negotiated price reduction combined with medical insurance reimbursement means that individuals only need to pay one-tenth of the original amount

36Kr

SL PHARM

CISEN

huahaipharm

Allmed Medical

National Healthcare Security Administration: Key drug "Deferasirox" for treating "thalassemia" included in medical insurance

02196

600196

China's pet obesity crisis is prompting interest in weight-loss drugs for animals, following a $2.1 billion deal between Fosun Pharma's Yao Pharma and Pfizer for an experimental obesity drug. Huadong Medicine is also seeking approval for similar veterinary drugs. The market potential is significant, with 40-50% of pets globally classified as overweight. The growing pet population and increasing humanization of pets are driving demand for advanced therapeutics. However, some pet owners are cautious about potential side effects, preferring dietary management over medication.

SCMP

FOSUN PHARMA

Meow or never: China’s pudgy pets spark race for weight-loss drugs

HUADONG MEDICINE(000963.SZ)

Assessing Grand Pharmaceutical Group (SEHK:512) Valuation After China Drug Approvals And Earnings Update

01:48 ETBelief BioMed and Grand Life Sciences Announced Exclusive Commercial Partnership in the Field of Hemophilia A, Bringing Innovative Gene Therapy to Chinese Patients

Grand Pharmaceutical Wins China’s First Approval for Demodex Blepharitis Drug, Bolstering Ophthalmic Push

East China Pharmaceutical Subsidiary Receives FDA Approval for Clinical Trial

National Healthcare Security Administration: Key drug "Deferasirox" for treating "thalassemia" included in medical insurance

Meow or never: China’s pudgy pets spark race for weight-loss drugs